nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.11.2017 | Review

Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options

verfasst von: A. A. Verhaegen, L. F. Van Gaal

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Weight gain is a common side effect of many widely used drugs. Weight gain of a few kilograms to an increase of 10% or more of initial body weight has been described. Not only the weight gain as such puts a burden on the health risks of the involved patients, the accompanying increase in the incidence of the metabolic syndrome, type 2 diabetes mellitus, and cardiovascular risk factors urges the caregiver to identify and to closely monitor the patients at risk. In this review, the different classes of drugs with significant weight gaining properties and the metabolic consequences are described. Specific attention is given to pathogenetic mechanisms underlying the metabolic effects and to potential therapeutic measures to prevent them.

http://www.who.int/mediacentre/factsheets/fs311/en/

Medici V, McClave SA, Miller KR (2016) Common medications which lead to unintended alterations in weight gain or organ lipotoxicity. Curr Gastroenterol Rep 18(1):2–12CrossRefPubMed

Domecq JP, Prutsky Gk KF, Lababidi MH et al (2015) Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab 100(2):363–370CrossRefPubMedPubMedCentral

Curtis JR, Westfall AO, Allison J et al (2006) Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55(3):420–426CrossRefPubMed

Wung PK, Anderson T, Fontaine KR et al (2008) Effects of glucocorticoids on weight change during the treatment of Wegener’s granulomatosis. Wegener’s Granulomatosis Etanercept Trial Research Group. Arthritis Rheum 59(5):746–753CrossRefPubMedPubMedCentral

Elster EA, Leeser DB, Morrissette C et al (2008) Obesity following kidney transplantation and steroid avoidance immunosuppression. Clin Transplant 22(3):354–359CrossRefPubMed

Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittmann G et al (2008) AMP-activated protein kinase mediates glucocorticoid induced metabolic changes: a novel mechanism in Cushing’s syndrome. FASEB J 22:1672–1683CrossRefPubMed

Bowles NP, Karatsoreos IN, Li X et al (2015) A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome. Proc Natl Acad Sci USA 112(1):285–290CrossRefPubMed

Petersons CJ, Mangelsdorf BL, Jenkins AB et al (2013) Effects of low-dose prednisolone on hepatic and peripheral insulin sensitivity, insulin secretion, and abdominal adiposity in patients with inflammatory rheumatologic disease. Diabetes Care 36:2822–2829CrossRefPubMedPubMedCentral

10.

Dube S, Slama MQ, Basu A, Rizza RA, Basu R (2015) Glucocorticoid excess increases hepatic 11β-HSD-1 activity in humans: implications in steroid-induced diabetes. J Clin Endocrinol Metab 100(11):4155–4162CrossRefPubMedPubMedCentral

11.

Wolf G (2002) Glucocorticoids in adipocytes stimulate visceral obesity. Nutr Rev 60(5 Pt 1):148–151PubMed

12.

Stomby A, Andrew R, Walker BR, Olsson T (2014) Tissue-specific dysregulation of cortisol regeneration by 11betaHSD1 in obesity: has it promised too much? Diabetologia 57(6):1100–1110CrossRefPubMed

13.

Van Gaal L, Scheen A (2015) Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care 38(6):1161–1172CrossRefPubMed

14.

Russell-Jones D, Khan R (2007) Insulin-associated weight gain in diabetes—causes, effects and coping strategies. Diabetes Obes Metab 6:799–812CrossRef

15.

Pontiroli AE, Miele L, Morabito A (2011) Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 13(11):1008–1019CrossRefPubMed

16.

Mäkimattila S, Nikkilä K, Yki-Yärvinen H (1999) Causes of weight gain during insulin therapy with and without metformin in patients with type 2 diabetes mellitus. Diabetologia 42:406–412CrossRefPubMed

17.

Hermansen K, Davies M (2007) Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab 9(3):209–217CrossRefPubMed

18.

UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865CrossRef

19.

Kahn SE, Haffner SM, Heise MA, F.R.C.P. for the ADOPT Study Group et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443CrossRefPubMed

20.

Wilding J (2006) Thiazolidinediones, insulin resistance and obesity: finding a balance. Int J Clin Pract 60:1272–1280CrossRefPubMed

21.

Sanyal AJ, Chalasani N, Kowdley KV et al (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362(18):1675–1685CrossRefPubMedPubMedCentral

22.

UK Prospective Diabetes Study Group (1995) Overview of 6 years’ therapy of type II diabetes: a progressive disease (UK prospective diabetes study 16). Diabetes 44:149–158CrossRef

23.

Apovian CM, Aronne LJ, Bessesen DH et al (2015) Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab 100(2):342–362CrossRefPubMed

24.

Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, Sowers J (2013) Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment—a position paper of The Obesity Society and The American Society of Hypertension. Obesity (Silver Spring) 21(1):8–24CrossRef

25.

Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC (2001) B-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 37:250–254CrossRefPubMed

26.

Messerli FH, Bell DS, Fonseca V, Investigators GEMINI et al (2007) Body weight changes with beta-blocker use: results of GEMINI. Am J Med 120(7):610–615CrossRefPubMed

27.

Clement K, Vaisse C, Manning BS et al (1995) Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 333:352–354CrossRefPubMed

28.

Welle S, Schwartz RG, Statt M (1991) Reduced metabolic rate during beta-adrenergic blockade in humans. Metabolism 40:619–622CrossRefPubMed

29.

Astrup A, Simonsen L, Bülow J, Madsen J, Christensen NJ (1989) Epinephrine mediates facultative carbohydrate-induced thermogenesis in human skeletal muscle. Am J Physiol 257(3 Pt 1):E340–E345PubMed

30.

Koch G, Franz IW, Lohmann FW (1981) Effects of short-term and long-term treatment with cardio-selective and non-selective beta-receptor blockade on carbohydrate and lipid metabolism and on plasma catecholamines at rest and during exercise. Clin Sci 61(suppl 7):433s–435sCrossRefPubMed

31.

Elliott WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369(9557):201–207CrossRefPubMed

32.

Pollare T, Lithell H, Selinus I, Berne C (1989) Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 298(6681):1152–1157CrossRefPubMedPubMedCentral

33.

Bakris GL, Fonseca V, Katholi RE, Investigators GEMINI et al (2004) Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292(18):2227–2236CrossRefPubMed

34.

Ripley TL, Saseen JJ (2014) β-blockers: a review of their pharmacological and physiological diversity in hypertension. Ann Pharmacother 48(6):723–733CrossRefPubMed

35.

Moore TJ, Mattison DR (2017) Adult utilization of psychiatric drugs and differences by sex, age, and race. JAMA Intern Med 177(2):274–275CrossRefPubMed

36.

Compton MT, Daumit GL, Druss BG (2006) Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: a preventive perspective. Harv Rev Psychiatry 14(4):212–222CrossRefPubMed

37.

Naughton M, Dinan TG, Scott LV (2014) Corticotropin-releasing hormone and the hypothalamic-pituitary-adrenal axis in psychiatric disease. Handb Clin Neurol 124:69–91CrossRefPubMed

38.

Ménard C, Pfau ML, Hodes GE, Russo SJ (2017) Immune and neuroendocrine mechanisms of stress vulnerability and resilience. Neuropsychopharmacology 42(1):62–80CrossRefPubMed

39.

Capuron L, Lasselin J, Castanon N (2017) Role of adiposity-driven inflammation in depressive morbidity. Neuropsychopharmacology 42(1):115–128CrossRefPubMed

40.

Chuang JC, Krishnan V, Yu HG et al (2010) A beta3-adrenergic-leptin-melanocortin circuit regulates behavioral and metabolic changes induced by chronic stress. Biol Psychiatry 67(11):1075–1082CrossRefPubMedPubMedCentral

41.

Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmächer T (2003) Epidemiology, implications and mechanisms underlying drug induced weight gain in psychiatric patients. J Psychiatr Res 37(3):193–220CrossRefPubMed

42.

Vandenberghe F, Gholam-Rezaee M, Saigí-Morgui N et al (2015) Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. J Clin Psychiatry 76(11):e1417–e1423CrossRefPubMed

43.

American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists et al (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27(2):596–601CrossRef

44.

Bernstein JG (1987) Induction of obesity by psychotropic drugs. Ann N Y Acad Sci 499:203–215CrossRefPubMed

45.

Smith GC, Vickers MH, Cognard E, Shepherd PR (2009) Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour. Schizophr Res 115(1):30–40CrossRefPubMed

46.

Stanhope KL, Havel PJ (2010) Fructose consumption: recent results and their potential implications. Ann N Y Acad Sci 1190:15–24CrossRefPubMedPubMedCentral

47.

Himmerich H, Minkwitz J, Kirkby KC (2015) Weight gain and metabolic changes during treatment with antipsychotics and antidepressants. Endocr Metab Immune Disord Drug Targets 15(4):252–260CrossRefPubMed

48.

Casey DE, Zorn SH (2001) The pharmacology of weight gain with antipsychotics. Clin Psych 62(suppl 7):4–10

49.

Bahra SM, Weidemann BJ, Castro AN et al (2015) Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. EBioMedicine 2(11):1725–1734CrossRefPubMed

50.

Oh JE, Cho YM, Kwak SN et al (2012) Inhibition of mouse brown adipocyte differentiation by second-generation antipsychotics. Exp Mol Med 44(9):545–553CrossRefPubMedPubMedCentral

51.

Pavan C, Vindigni V, Michelotto L et al (2010) Weight gain related to treatment with atypical antipsychotics is due to activation of PKC-β. Pharmacogenomics J 10(5):408–417CrossRefPubMed

52.

Everard A, Cani PD (2013) Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol 27(1):73–83CrossRefPubMed

53.

Flowers SA, Evans SJ, Ward KM, McInnis MG, Ellingrod VL (2017) Interaction between atypical antipsychotics and the gut microbiome in a bipolar disease cohort. Pharmacotherapy 37(3):261–267CrossRefPubMed

54.

Shams TA, Müller DJ (2014) Antipsychotic induced weight gain: genetics, epigenetics, and biomarkers reviewed. Curr Psychiatry Rep 16(10):473CrossRefPubMed

55.

Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Müller DJ (2012) Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry 17(3):242–266CrossRefPubMed

56.

Serreti A, Mandelli L (2010) Antidepresants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 71(10):1259–1272CrossRef

57.

Massand PS, Gupta S (2002) Long term side effects of newer generation antidepressants SSRIS, venlafaxine, nefazodone, bupropion and mirtazapine. Ann Clin Psychiatry 14(3):175–182CrossRef

58.

Gadde KM, Xiong GL (2007) Bupropion for weight reduction. Expert Rev Neurother 7(1):17–24CrossRefPubMed

59.

Billes SK, Sinnayah P, Cowley MA (2014) Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res 84:1–11CrossRefPubMed

60.

Livingstone C, Rampes H (2006) Lithium: a review of its metabolic adverse effects. J Psychopharmacol 20(3):347–355CrossRefPubMed

61.

Chen Y, Silverstone T (1990) Lithium and weight gain. Int Clin Psychopharmacol 5(3):217–225CrossRefPubMed

62.

Sohn M, Moga DC, Blumenschein K, Talbert J (2016) National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. Medicine (Baltimore) 95(23):e3784CrossRef

63.

Verdoux H, Tournier M, Bégaud B (2010) Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 121(1):4–10CrossRefPubMed

64.

Allison DB, Mentore JL, Heo M et al (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156(11):1686–1696PubMed

65.

Allison DB, Casey DE (2001) Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62(Suppl 7):22–31PubMed

66.

Balf G, Stewart DT, Whitehead R, Baker RA (2008) Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective. Prim Care Companion J Clin Psychiatry 10(1):15–24CrossRefPubMedPubMedCentral

67.

Orsolini L, Tomasetti C, Valchera A et al (2016) An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf 15(10):1329–1347CrossRefPubMed

68.

Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302(16):1765–1773CrossRefPubMedPubMedCentral

69.

Hoffmann VP, Case M, Stauffer VL, Jacobson JG, Conley RR (2010) Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled trials. J Clin Psychopharmacol 30(6):656–660CrossRefPubMed

70.

Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ (2005) Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 5:3CrossRefPubMedPubMedCentral

71.

Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis. Schizophr Bull 39(2):306–318CrossRefPubMed

72.

Holt RI, Peveler RC (2006) Association between antipsychotic drugs and diabetes. Diabetes Obes Metab 8(2):125–135CrossRefPubMed

73.

De Hert M, Detraux J, van Winkel R, Yu W, Correll CU (2011) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8(2):114–126CrossRefPubMed

74.

Ballon JS, Pajvani U, Freyberg Z, Leibel RL, Lieberman JA (2014) Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol Metab 25(11):593–600CrossRefPubMed

75.

Dwyer DS, Donohoe D (2003) Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav 75(2):255–260CrossRefPubMed

76.

Daumit GL, Goff DC, Meyer JM et al (2008) Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 105(1–3):175–187CrossRefPubMedPubMedCentral

77.

Ben-Menachem E (2007) Weight issues for people with epilepsy—a review. Epilepsia 48(Suppl 9):42–45CrossRefPubMed

78.

Verrotti A, D’Egidio C, Mohn A, Coppola G, Chiarelli F (2011) Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev 12(5):e32–e43CrossRefPubMed

79.

Belcastro V, D’Egidio C, Striano P, Verrotti A (2013) Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res 107(1–2):1–8CrossRefPubMed

80.

Wong HY, Chu TS, Lai JC et al (2005) Sodium valproate inhibits glucose transport and exacerbates Glut1-deficiency in vitro. J Cell Biochem 96(4):775–785CrossRefPubMed

81.

Farinelli E, Giampaoli D, Cenciarini A, Cercado E, Verrotti A (2015) Valproic acid and nonalcoholic fatty liver disease: a possible association? World J Hepatol 7(9):1251–1257CrossRefPubMedPubMedCentral

82.

Swann AC (2001) Major system toxicities and side effects of anticonvulsants. J Clin Psychiatry 62(suppl 14):16–21PubMed

83.

Antel J, Hebebrand J (2012) Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. Handb Exp Pharmacol 209:433–466CrossRef

84.

Smith SM, Meyer M, Trinkley KE (2013) Phentermine/topiramate for the treatment of obesity. Ann Pharmacother 47(3):340–349CrossRefPubMed

85.

Gierisch JM, Nieuwsma JA, Bradford DW et al (2013) Interventions to improve cardiovascular risk factors in people with serious mental illness [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US). Report No.: 13-EHC063-EF. AHRQ Comparative Effectiveness Reviews

86.

Green CA, Yarborough BJ, Leo MC et al (2015) The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Obesity (Silver Spring) 23(10):1995–2001CrossRef

87.

Alvarez-Jiménez M, Hetrick SE, González-Blanch C, Gleeson JF, McGorry PD (2008) Non pharmacological management of antipsychotic-induced weight gain: systematic review and meta analysis of randomised controlled trials. Br J Psychiatry 193(2):101–107CrossRefPubMed

88.

Newcomer JW, Weiden PJ, Buchanan RW (2013) Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice. J Clin Psychiatry 74(11):1108–1120CrossRefPubMed

89.

Hasnain M, Vieweg WV (2013) Weight considerations in psychotropic drug prescribing and switching. Postgrad Med 125(5):117–129CrossRefPubMed

90.

Mukundan A, Faulkner G, Cohn T, Remington G (2010) Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev (12):CD006629. doi:10.1002/14651858.CD006629.pub2

91.

Mizuno Y, Suzuki T, Nakagawa A et al (2014) Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 40(6):1385–1403CrossRefPubMedPubMedCentral

92.

Zheng W, Li XB, Tang YL, Xiang YQ, Wang CY, de Leon J (2015) Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol 35(5):499–509CrossRefPubMed

93.

Hu Y, Young AJ, Ehli EA et al (2014) Metformin and berberine prevent olanzapine-induced weight gain in rats. PLoS One 9(3):e93310CrossRefPubMedPubMedCentral

94.

Ebdrup BH, Knop FK, Ishøy PL et al (2012) Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. BMC Med 10:92CrossRefPubMedPubMedCentral

95.

Lykkegaard K, Larsen PJ, Vrang N, Bock C, Bock T, Knudsen LB (2008) The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr Res 103(1–3):94–103CrossRefPubMed

96.

Sharma AN, Ligade SS, Sharma JN, Shukla P, Elased KM, Lucot JB (2015) GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats. Metab Brain Dis 30(2):519–527CrossRefPubMed

97.

Larsen JR, Vedtofte L, Jakobsen MSL et al (2017) Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine-or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2017.1220 PubMed

98.

Müller N (2010) COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr Opin Investig Drugs 11(1):31–42PubMed

99.

Gross C, Blasey CM, Roe RL, Belanoff JK (2010) Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. Obesity (Silver Spring.) 18(12):2295–2300CrossRef

100.

Belanoff JK, Blasey CM, Clark RD, Roe RL (2010) Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain. Diabetes Obes Metab 12(6):545–547CrossRefPubMed

101.

Rimessi A, Pavan C, Ioannidi E et al (2017) Protein kinase C β: a new target therapy to prevent the long-term atypical antipsychotic-induced weight gain. Neuropsychopharmacology 42(7):1491–1501CrossRefPubMed

Titel: Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options
verfasst von: A. A. Verhaegen
L. F. Van Gaal
Publikationsdatum: 01.11.2017
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 11/2017
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-017-0719-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2017

Tall cell and diffuse sclerosing variants of papillary thyroid cancer: outcome and predicting value of risk stratification methods

Luciano Martini (1927–2017): a memoir

The baptism of the Princes of Marseille Gaudenzio Ferrari (1475–1546)

Transoral thyroidectomy: advantages and limitations

Familial hypocalciuric hypercalcemia type 1 due to a novel homozygous mutation of the calcium-sensing receptor gene